We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Salvarx Group Plc | LSE:SALV | London | Ordinary Share | IM00BZ4SS228 | ORD 2.5P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 4.50 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
From Apr 2019 to Apr 2024
TIDMSALV
RNS Number : 8421E
SalvaRx Group plc
09 July 2019
9 July 2019
SalvaRx Group plc
("SalvaRx" or the "Company")
Suspension of Trading
SalvaRx announces that trading in the Company's ordinary shares on AIM will be suspended with effect from 7.30 a.m. today.
The suspension is due to the Company not having made an acquisition or acquisitions which would constitute a reverse takeover under AIM Rule 14 ("Reverse Takeover"), or having been re-admitted to trading on AIM as an investing company under the AIM Rules, on or before the date falling six months from the Company's Annual General Meeting when it was classified as an AIM Rule 15 cash shell.
Trading in the Company's ordinary shares will remain suspended until the completion of a Reverse Takeover, which requires the publication of an admission document and the approval of such a transaction at a general meeting of the Company, or the Company is re-admitted to trading on AIM as an investing company. If no such transaction is completed within six months the Company's shares will be cancelled from trading on AIM pursuant to AIM Rule 41.
The Board continues to seek suitable opportunities for a Reverse Takeover and will make a further announcement at the appropriate time.
Enquiries
SalvaRx Group plc Tel: +44 (0) 01624 Denham Eke 639396 SP Angel Corporate Finance LLP Tel: +44 (0) 20 Nominated Adviser and Broker 3470 0470 Matthew Johnson / Jamie Spotswood (Corporate Finance) Abigail Wayne (Corporate Broking) Peterhouse Corporate Finance Limited Tel: +44 (0) 20 Joint Broker 7469 0932 Lucy Williams / Duncan Vasey
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
SRSUGUCWMUPBGCR
(END) Dow Jones Newswires
July 09, 2019 04:35 ET (08:35 GMT)
1 Year Salvarx Chart |
1 Month Salvarx Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
